Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MC-1020 is an investigational cannabidiol (CBD) formulation developed by Medlab Clinical, delivered via an oro-buccal spray. The product utilizes Medlab's proprietary NanoCelle sub-micron nanoparticle delivery platform, which is designed to enhance the solubility and absorption of lipophilic molecules like CBD through the oral mucosa. By bypassing the gastrointestinal tract and first-pass hepatic metabolism, MC-1020 aims to provide faster onset and improved bioavailability compared to traditional oral CBD oils. It is being investigated for the treatment of anxiety disorders, leveraging CBD's activity as a modulator of the endocannabinoid system and an agonist at serotonin 5-HT1A receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MC-1020.